{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-005633","form_type":"8-K","ticker":null,"cik":"0001828522","company_name":"eFFECTOR Therapeutics, Inc.","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.784426+00:00","generated_at":"2026-06-07T01:02:14.532912+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"eFFECTOR Therapeutics to effect 1-for-25 reverse stock split on Jan 12, 2024","bullets":["Reverse stock split of 1-for-25 effective at 12:01 a.m. ET on Jan 12, 2024.","Outstanding shares reduce from approx. 74.9M to approx. 3.0M; authorized shares cut from 1B to 40M.","Par value unchanged; no fractional shares issued, cash paid for fractional interests.","Trading on Nasdaq on split-adjusted basis begins at market open Jan 12; new CUSIP 28202V207 for common."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-005633","json":"https://secwatch.observer/filing/0001193125-24-005633.json","markdown":"https://secwatch.observer/filing/0001193125-24-005633.md","text":"https://secwatch.observer/filing/0001193125-24-005633.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524005633/0001193125-24-005633-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524005633/d435653d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:02:14.532912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d62e5bc8d11ac3fb70f003c3ebc125025e731b13","claim":"eFFECTOR Therapeutics, Inc.: Amendment to certificate of incorporation to effectuate a 1-for-25 reverse stock split, reducing authorized shares proportionally (effective 2024-01-12).","evidence_excerpt":"On January 9, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) filed an amendment (the “Amendment”) to its amended and restated certificate of incorporation to effectuate a reverse stock split of the Company’s common stock, par value $0.0001per share (“Common Stock”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524005633/0001193125-24-005633-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-01-12"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}